Genital herpes (GH), historically associated with herpes simplex virus type 2 (HSV-2), is changing its etiology. Since the last few decades, there has been an increase in genital infections caused by herpes simplex virus type 1 (HSV-1). In fact, in several countries, preferably in high-income regions such as North America or Western Europe, HSV-1 has become the leading cause of first-episode GH, especially among adolescents and young adults. However, the epidemiological trend varies geographically, with slower changes observed in Africa, Latin America, and Southeast Asia, where GH HSV-2 remains dominant. This epidemiological shift may be mainly due to the decline in HSV-1 seroprevalence, decreased childhood exposure to the virus, and changes in sexual practices. Despite the global decline in HSV-1 seroprevalence, GH caused by HSV-1 is rising by 1 to 2% annually in many areas. This review summarizes the seroprevalence of HSV-1/-2 worldwide in recent decades and discusses the changes in GH etiology and contributing factors. Despite the substantial global burden of the disease and its psychosocial impact, no vaccine or curative treatment exists. Active surveillance, health education, and targeted interventions are vital to manage this changing landscape and to mitigate the public health issue posed by GH and HSV-1.
In addition to its classical role in calcium and phosphate metabolism regulation, vitamin D also has an important impact on immunity modulation. Vitamin D regulates the immune response, shifting from a proinflammatory state to a more tolerogenic one by increasing the release of anti-inflammatory cytokines while downregulating proinflammatory cytokines. Thus, low levels of vitamin D have been associated with an increased risk of developing autoimmune diseases like multiple sclerosis and type 1 diabetes. Furthermore, this prohormone also enhances the release of well-known antimicrobial peptides, like cathelicidin LL-37 and β-defensins; therefore, it has been proposed that vitamin D serum levels might be related to the risk of well-known pathogen infections, including herpesviruses. These are a group of widely spread viral pathogens that can cause severe encephalitis or tumors like Kaposi’s sarcoma and Burkitt lymphoma. However, there is no consensus on the minimum levels of vitamin D or the recommended daily dose, making it difficult to establish a possible association between these two factors. This narrative non-systematic review will analyze the mechanisms by which vitamin D regulates the immune system and recent studies about whether there is an association between vitamin D serum levels and herpesvirus infections.
Herpes simplex viruses (HSV‐1 and HSV‐2) are highly prevalent and contagious, causing lifelong infections that cannot be eradicated with current therapies. Acyclovir and other viral DNA polymerase inhibitors are effective antiviral agents for treating HSV infections. However, despite the recent approval of pritelivir and amenamevir (helicase–primase complex inhibitors), drug resistance is still a major threat to therapeutic success. This research focuses on developing new antiviral strategies against HSV‐1 by targeting the pUL15 endonuclease, a component of the viral packaging motor/terminase complex, using substituted polycyclic pyridones derived from baloxavir acid. Several compounds display low micromolar IC 50 values in enzymatic assays. Among them, the prioritized compound, LN‐7 , shows a 50% effective concentration (EC 50 ) of 2.8 ± 1.1 µ m in antiviral assays and favorable pharmacokinetic properties in rats. LN‐7 demonstrates antiviral efficacy in infected mice, while exhibiting fewer clinical signs compared to controls. Overall, LN‐7 emerges as a promising lead for treating herpesvirus infections and is therefore a first‐in‐class drug candidate targeting HSV genome packaging.
The most common marker used to monitor autophagy is the microtubule-associated protein light chain 3 (LC3). Upon induction of autophagy, LC3 is conjugated to phosphatidylethanolamine and targeted to autophagic membranes, which can be easily detected by immunofluorescence. However, this technique has some limitations. During the early stages of HSV-1 infection, strong LC3B nuclear staining is observed within the viral replication compartments. This staining is only detected when using polyclonal antibodies. It is noteworthy that monoclonal antibodies or the GFP-LC3 plasmid do not reveal any nuclear LC3 staining. Interestingly, LC3B is not detected in the nuclear fraction of infected cells by Western blotting, even when polyclonal antibodies are used. In infected LC3B knockout cells, nuclear staining is still observed when using polyclonal LC3B antibodies. This suggests that polyclonal LC3B antibodies generate non-specific nuclear staining in infected cells, which could result in misinterpretation and erroneous conclusions. These findings raise questions about the reliability of LC3-immunofluorescence assays in herpesvirus infections. It is imperative that the methodology employed for monitoring autophagy by immunofluorescence in viral infections be reviewed and updated, and that the specificity of anti-LC3B antibodies be tested before use. To ensure the accuracy of the results, it is essential to validate this technique with additional assays, such as by immunoblot analysis or via the use of autophagy-deficient cell lines.